Evaluating SLI-F06 for improving scar appearance in healthy volunteers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase IIa interventional study assesses the safety and efficacy of SLI-F06 in improving scar appearance through a multi-center, double-blind approach. Healthy volunteers aged 18 to 65 will undergo small punch biopsies on their upper and lower backs, with excisions randomized to receive either SLI-F06 or a vehicle control. Participants will be divided into three cohorts, each receiving different dosing regimens, and scars will be evaluated for improvement over a follow-up period of 6-9 months. The study aims to determine the optimal dose regimen for enhancing wound healing and scar appearance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Healthy subjects, male or female, ages 18 to 65
2. Subjects with a Body Mass Index (BMI) 18.5-30 and at least 40 kg
3. Subjects with symmetrically located right and left scapular lines relative to the midline, and at least 12 cm distance between the right and left scapular lines.
4. Be able to follow study instructions and likely to complete all required visits.
5. Sign the Institutional Review Board (IRB)-approved informed consent form (ICF, which includes the Photographic and Video Release Form) prior to any study-related procedures being performed.

Exclusion Criteria:

1. Female subjects who are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control methods
2. Subjects who were previously treated with SLI-F06
3. Subjects with evidence of hypertrophic or keloid scarring
4. Subjects with obvious back abnormalities (e.g., severe scoliosis)
5. Subjects with tattoos or previous scars in the study areas
6. Subjects who are poor surgical candidates

   1. Active disease that could interfere with or limit wound healing (e.g., diabetes, anemia, renal disease, hepatic disease, cardiac disease, or immune system disorders)
   2. History of clinically significant bleeding disorder or coagulation disorders
   3. Use of any tobacco/inhaled nicotine products including vaping within 12 months.
7. Subjects with evidence of skin infection or rash on the back
8. Subjects with history of active or uncontrolled skin disease (e.g., psoriasis, eczema, rosacea, vitiligo, skin cancer) that could interfere with the study or interpretation of the study outcomes
9. Subjects with a history of clinically significant allergies, especially drug hypersensitivity to lignocaine or allergy to adhesive surgical dressings
10. Subjects with any clinically significant abnormality following review of pre-study laboratory data and full physical examination
11. Subjects who are taking or have taken known anticoagulants:

    1. Blood thinners (e.g., coumadin, rivaroxaban, apixaban) within 2 months prior to day 0
    2. Others such as aspirin or aspirin containing products, Non-steroidal anti-inflammatory drugs (NSAIDs), vitamin E, fish oil within 14 days prior to day 0.
12. Subjects taking systemic or topical steroids within 4 weeks of Day 0
13. Subjects with excessive alcohol use, defined as \>28 units of alcohol per week (1unit = 8 g alcohol, 1shot spirits, half- pint beer, or 5 oz wine)
14. Subjects who have evidence of drug abuse
15. Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen per medical history
16. Subjects with a history of poor or delayed wound healing (e.g., prior wound dehiscence, chronic wound, leg ulcer)
17. Subjects treated with an investigational drug or device within 30 days prior to day 0
18. Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, or may significantly interfere with the subject's participation in the study

Where it's running

• California Dermatology & Clinical Research Institute
  Encinitas, California, United States Recruiting
• DermResearch
  Austin, Texas, United States Recruiting

Study contacts

• Study coordinator: Elisabeth J Leeflang, MD
• Email: ELeeflang@scarlesslabs.com
• Phone: 213-788-2128

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lactoferrin Gel for Healing and Implant Stability in Immediate Mandibular Molars

  A 4% bovine lactoferrin nanohydrogel is being tested to see if it helps soft tissue and bone heal better and improve implant stability after immediate mandibular molar implants.

  Recruiting Phase 2/3 Future University in Egypt · Cairo, Cairo Governorate · NCT07889674

• Curcumin topical spray for healing after a first molar extraction

  This study tests whether a curcumin spray applied to the extraction site helps healing and reduces pain compared with chlorhexidine spray or standard care in healthy adults undergoing a first molar extraction.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07874789

• Disposable noninvasive skin closure to help healing and reduce scarring after plastic surgery

  This study tests a disposable noninvasive skin closure device on one side of a plastic surgery incision to see if it helps wounds heal better and results in less scarring.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07849010

• Calcaneal Bone Marrow Cells in Foot/Ankle Surgery Patients

  This observational study tests whether routine preoperative blood tests relate to the quality and behavior of mesenchymal stem cells from calcaneal bone marrow in adults undergoing foot or ankle surgery.

  Recruiting Universidade Sao Francisco · Bragança Paulista, São Paulo · NCT07802106

• Obesity and normal-weight healing after gum graft surgery using collagen plug or PRF

  This study tests whether healing after a gum graft differs by weight class (obese vs. normal weight) and compares platelet-rich fibrin clot to the standard collagen plug.

  Recruiting University of Iowa · Iowa City, Iowa · NCT07756112

• Early Wound Healing and Outcomes of Regenerative Periodontal Surgery

  This study looks to see if healing in the first 1–2 weeks after periodontal regenerative surgery can predict how well the treatment works at 12 months in people with advanced periodontitis.

  Recruiting University of Roma La Sapienza · Rome, Rome · NCT07683962

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.